Please login to the form below
Richard Ranieri leaves Dendreon for Biomarin
Will head human resources and corporate affairs
BioMarin Pharmaceutical has named former Dendreon executive VP Richard Ranieri as senior VP, human resources and corporate affairs.
Ranieri spent three years in his position at Dendreon, having joined from Sepracor where he was executive VP, human resource and administration.
He has also served in executive positions at Neurocrine Biosciences, Genencor International and Smithkline Beecham.
“He brings a wealth of human resources experience to the company as we continue our rapid growth,” said Jean-Jacques Bienaime, CEO of BioMarin.
“He has the depth and breadth of global experience that BioMarin needs as it scales its operations to meet its expanding business."
This expanding business includes the company's poly ADP ribose polymerase (PARP) inhibitor BMN-673, which is being studied in several cancer indications.
Subscribe to our email news alerts
- Clairvoyant commercialisation
- Planting the Seeds for Future Women Leaders in Medicine
- FDA approves SpringWork’s Ogsiveo as first therapy for desmoid tumours
- GSK shares positive phase 3 results for Blenrep combination in multiple myeloma
- Stem cell therapy trial shows promising results for treating progressive MS
- Cancer Research UK calls on government to create ten-year cancer plan
No results were found
PMHub
Onyx Health
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
